Clinical trials: Biliary Cancers
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.
- Trial name
- NCT06778031
- Testing
- SHR-A1811, SHR-1316, SHR-8068
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cholangiocarcinoma
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in…
- Trial name
- RELEASE (NCT04099888)
- Testing
- Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 41 people
- Sponsor
- PCI Biotech AS
Biliary Tract Cancer, Periampullary Adenocarcinoma
SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer…
- Conditions
- Biliary Tract Cancer, Periampullary Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT01811277
- Testing
- SOX sequential S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Biliary Tract Cancer
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
- Trial name
- TOURMALINE (NCT05771480)
- Testing
- Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin
- Where
- 34 sites in United States, France and 6 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Pancreatic Neoplasms, Biliary Tract Neoplasms
The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer
The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.
- Trial name
- NCT00268840
- Testing
- Docetaxel, Gemcitabine
- Where
- France
- Volunteers
- 45 people
- Sponsor
- ARCAGY/ GINECO GROUP
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Biliary Tract Diseases, Gallbladder Cancer
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer
The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder.
- Conditions
- Biliary Tract Diseases, Gallbladder Cancer, Gallbladder Neoplasms
- Trial name
- CRGGCext (NCT06276153)
- Testing
- no interventions
- Volunteers
- 5,000 people
- Sponsor
- RenJi Hospital
Biliary Tract Cancer
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
This study is to test the efficacy of MEK162 plus capecitabine in gemcitabine-pretreated advanced biliary tract cancer, and to explore the predictive biomarkers for future large-scale clinical trials using this combination.
- Trial name
- NCT02773459
- Testing
- MEK162+capecitabine
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Seoul National University Hospital
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Biliary Cancer
Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.
The purpose of this study is to compare the duration of stent patency of a covered vs. an uncovered biliary self-expandable metal stents (SEMS) placed to relieve biliary obstruction in patients with inoperable extrahepatic…
- Trial name
- SEMS (NCT02930252)
- Testing
- Niti-S Biliary ComVi Stent, Niti-S stent (D type)
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- Azienda USL 1 Imperiese
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Bile Duct Neoplasms, Jaundice, Obstructive
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
The goal of this observational study is to detect the methylation characteristics of cfDNA in the bile and plasma of patients with bile duct stricture.
- Conditions
- Bile Duct Neoplasms, Jaundice, Obstructive, Bile Duct Diseases
- Trial name
- NCT06115655
- Testing
- cfDNA methylation detection
- Where
- China
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Ampullary Adenomas
EP Combined With RFA for Ampullary Neoplasms With Intraductal Biliary Extension
Endoscopic papillectomy is the preferred approach for management of ampullary adenomas. Endobiliary radiofrequency ablation (RFA) is an ablative therapy that has been used to treat malignant biliary strictures.
- Trial name
- NCT05028465
- Testing
- Endoscopic Papillectomy, Endobiliary Radiofrequency Ablation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- First People's Hospital of Hangzhou
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Non-small Cell Lung Cancer, Gastric Cancer
Early Palliative Care on Quality of Life of Advanced Cancer Patients
This study compares two types of care - Standard Oncology Care (SOC) and SOC with early palliative care (EPC) (started within 8 weeks after diagnosis of advanced disease) to see which is better for improving the quality of life…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT02988635
- Testing
- Early Palliative Care
- Volunteers
- 281 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.